Viking Therapeutics VKTX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $165.81M+522% | $26.68M-51.9% | $55.52M+51.6% | $36.63M+38.9% | ||
| $539.93M-38.4% | $875.94M+186% | $306.56M+158% | $118.85M-32.4% | ||
| $715.6M-21.1% | $907.22M+147% | $367.23M+120% | $167.04M-20.7% | ||
| $715.73M-21.2% | $908.32M+146% | $368.49M+119% | $168.53M-20.0% | ||
| $53.25M+443% | $9.81M+30.6% | $7.51M-11.9% | $8.53M+491% | ||
| $76.67M+180% | $27.41M+43.3% | $19.14M-12.8% | $21.95M+150% | ||
| $76.67M+173% | $28.04M+39.7% | $20.07M-13.5% | $23.21M+164% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| -$847.55M-73.7% | -$487.91M-29.1% | -$377.94M-29.4% | -$292.05M-30.9% | ||
| $639.06M-27.4% | $880.28M+153% | $348.42M+140% | $145.32M-28.0% | ||
| $715.73M-21.2% | $908.32M+146% | $368.49M+119% | $168.53M-20.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Viking Therapeutics cover its short-term obligations?
- Its current ratio is 5.72 — current assets exceed current liabilities.
- Where does Viking Therapeutics's balance sheet data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.